FY2027 EPS Estimate for Boston Scientific Lowered by Analyst

Boston Scientific Corporation (NYSE:BSX) – Research analysts at Erste Group Bank decreased their FY2027 earnings estimates for shares of Boston Scientific in a research note issued on Wednesday, February 18th. Erste Group Bank analyst H. Engel now forecasts that the medical equipment provider will post earnings per share of $3.92 for the year, down from their prior forecast of $3.94. The consensus estimate for Boston Scientific’s current full-year earnings is $2.85 per share.

BSX has been the subject of several other research reports. Needham & Company LLC lowered their price objective on Boston Scientific from $121.00 to $97.00 and set a “buy” rating for the company in a research report on Thursday, February 5th. JPMorgan Chase & Co. lowered their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, February 5th. Oppenheimer cut their price target on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a report on Friday, January 16th. National Bank Financial set a $115.00 price objective on shares of Boston Scientific in a research report on Monday, February 2nd. Finally, UBS Group dropped their target price on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $108.36.

Boston Scientific Trading Up 1.2%

Shares of BSX stock opened at $75.27 on Monday. The business has a 50-day moving average of $88.52 and a 200 day moving average of $96.13. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.62 and a quick ratio of 1.08. Boston Scientific has a 1-year low of $72.69 and a 1-year high of $109.50. The stock has a market capitalization of $111.70 billion, a PE ratio of 38.80, a P/E/G ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The business had revenue of $5.29 billion during the quarter, compared to analyst estimates of $5.29 billion. During the same period in the prior year, the business posted $0.70 earnings per share. The company’s revenue was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares in the company, valued at $2,396,580. This trade represents a 42.32% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Boston Scientific

A number of large investors have recently made changes to their positions in BSX. FWL Investment Management LLC purchased a new position in shares of Boston Scientific during the second quarter valued at approximately $26,000. Steph & Co. bought a new stake in shares of Boston Scientific during the 3rd quarter worth approximately $25,000. Murphy & Mullick Capital Management Corp boosted its holdings in Boston Scientific by 200.0% during the 3rd quarter. Murphy & Mullick Capital Management Corp now owns 255 shares of the medical equipment provider’s stock valued at $25,000 after acquiring an additional 170 shares during the period. Financial Consulate Inc. bought a new position in Boston Scientific in the 3rd quarter valued at $25,000. Finally, Swiss RE Ltd. purchased a new stake in Boston Scientific in the fourth quarter worth $26,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.